Intracoronary tirofiban: Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
Saline 0.9%: Patients will receive intracoronary saline 0.9% solution as a control group.
Study summary
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years old.
* Both sexes.
* Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Exclusion Criteria:
* Treatment with thrombolytic drugs in the previous 24 hours.
* Known malignancy.
* Thrombocytopenia.
* End-stage liver disease.
* Cardiogenic shock.
* Renal failure with glomerular filtration\<30 ml/min.
* Contraindication for the use of tirofiban.
Primary outcome measure(s)
Blood stream — After treatment (Up to 15 minutes) Blood stream in coronary artery before and after treatment, including Thrombolysis in Myocardial Infarction (TIMI) flow grade in IRAs, coronary blood flow will be calculated with TIMI frame count method.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.